APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gene Therapy in CNS Disorder

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Gene Therapy in CNS Disorder Market Analysis and Forecast 2026-2032

21 December 2025190 pages

Choose your research edition.

Industry ResearchGene Therapy in CNS Disorder Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Gene Therapy in CNS Disorder Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Gene Therapy in CNS Disorder Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gene Therapy in CNS Disorder Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Gene Therapy in CNS Disorder Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Gene Therapy in CNS Disorder market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Gene Therapy in CNS Disorder is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Gene Therapy in CNS Disorder is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Gene Therapy in CNS Disorder is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Gene Therapy in CNS Disorder is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Gene Therapy in CNS Disorder include Novartis AG, Biogen, Voyager Therapeutics, Spark Therapeutics and Bluebird Bio Inc., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Gene Therapy in CNS Disorder, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Gene Therapy in CNS Disorder, also provides the revenue of main regions and countries. Of the upcoming market potential for Gene Therapy in CNS Disorder, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Gene Therapy in CNS Disorder revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Gene Therapy in CNS Disorder market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Gene Therapy in CNS Disorder revenue, projected growth trends, production technology, application and end-user industry.

Gene Therapy in CNS Disorder Segment by Company

Novartis AG

Biogen

Voyager Therapeutics

Spark Therapeutics

Bluebird Bio Inc.

Gene Therapy in CNS Disorder Segment by Type

Viral Gene Therapy

Non-viral Gene Therapy

Gene Therapy in CNS Disorder Segment by Application

Parkinson's Disease

Huntington's Disease

Batten Disease

Alzheimer's Disease

Gene Therapy in CNS Disorder Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gene Therapy in CNS Disorder market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gene Therapy in CNS Disorder and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gene Therapy in CNS Disorder.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Gene Therapy in CNS Disorder in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Gene Therapy in CNS Disorder company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Gene Therapy in CNS Disorder revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Gene Therapy in CNS Disorder Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Viral Gene Therapy Major Player Table 3. Non-viral Gene Therapy Major Player Table 4. Global Gene Therapy in CNS Disorder Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Parkinson's Disease Major Player Table 6. Huntington's Disease Major Player Table 7. Batten Disease Major Player Table 8. Alzheimer's Disease Major Player Table 9. Gene Therapy in CNS Disorder Industry Trends Table 10. Gene Therapy in CNS Disorder Industry Drivers Table 11. Gene Therapy in CNS Disorder Industry Opportunities and Challenges Table 12. Gene Therapy in CNS Disorder Industry Restraints Table 13. Global Gene Therapy in CNS Disorder Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Gene Therapy in CNS Disorder Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Gene Therapy in CNS Disorder Market Share by Region (2021-2026) Table 16. Global Gene Therapy in CNS Disorder Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Gene Therapy in CNS Disorder Market Share by Region (2027-2032) Table 18. Global Gene Therapy in CNS Disorder Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Gene Therapy in CNS Disorder Revenue Market Share by Players (2021-2026) Table 20. Global Gene Therapy in CNS Disorder Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Gene Therapy in CNS Disorder Key Players Headquarters & Area Served Table 22. Global Gene Therapy in CNS Disorder Players, Product Type & Application Table 23. Global Gene Therapy in CNS Disorder Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Gene Therapy in CNS Disorder by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Gene Therapy in CNS Disorder Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Gene Therapy in CNS Disorder Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Gene Therapy in CNS Disorder Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Gene Therapy in CNS Disorder Revenue Market Share by Type (2021-2026) Table 30. Global Gene Therapy in CNS Disorder Revenue Market Share by Type (2027-2032) Table 31. Global Gene Therapy in CNS Disorder Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Gene Therapy in CNS Disorder Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Gene Therapy in CNS Disorder Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Gene Therapy in CNS Disorder Revenue Market Share by Application (2021-2026) Table 35. Global Gene Therapy in CNS Disorder Revenue Market Share by Application (2027-2032) Table 36. Novartis AG Company Information Table 37. Novartis AG Business Overview Table 38. Novartis AG Gene Therapy in CNS Disorder Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Novartis AG Gene Therapy in CNS Disorder Product Portfolio Table 40. Novartis AG Recent Development Table 41. Biogen Company Information Table 42. Biogen Business Overview Table 43. Biogen Gene Therapy in CNS Disorder Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Biogen Gene Therapy in CNS Disorder Product Portfolio Table 45. Biogen Recent Development Table 46. Voyager Therapeutics Company Information Table 47. Voyager Therapeutics Business Overview Table 48. Voyager Therapeutics Gene Therapy in CNS Disorder Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Voyager Therapeutics Gene Therapy in CNS Disorder Product Portfolio Table 50. Voyager Therapeutics Recent Development Table 51. Spark Therapeutics Company Information Table 52. Spark Therapeutics Business Overview Table 53. Spark Therapeutics Gene Therapy in CNS Disorder Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Spark Therapeutics Gene Therapy in CNS Disorder Product Portfolio Table 55. Spark Therapeutics Recent Development Table 56. Bluebird Bio Inc. Company Information Table 57. Bluebird Bio Inc. Business Overview Table 58. Bluebird Bio Inc. Gene Therapy in CNS Disorder Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Bluebird Bio Inc. Gene Therapy in CNS Disorder Product Portfolio Table 60. Bluebird Bio Inc. Recent Development Table 61. North America Gene Therapy in CNS Disorder Revenue by Type (2021-2026) & (US$ Million) Table 62. North America Gene Therapy in CNS Disorder Revenue by Type (2027-2032) & (US$ Million) Table 63. North America Gene Therapy in CNS Disorder Revenue by Application (2021-2026) & (US$ Million) Table 64. North America Gene Therapy in CNS Disorder Revenue by Application (2027-2032) & (US$ Million) Table 65. North America Gene Therapy in CNS Disorder Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 66. North America Gene Therapy in CNS Disorder Revenue by Country (2021-2026) & (US$ Million) Table 67. North America Gene Therapy in CNS Disorder Revenue by Country (US$ Million) & (2027-2032) Table 68. Europe Gene Therapy in CNS Disorder Revenue by Type (2021-2026) & (US$ Million) Table 69. Europe Gene Therapy in CNS Disorder Revenue by Type (2027-2032) & (US$ Million) Table 70. Europe Gene Therapy in CNS Disorder Revenue by Application (2021-2026) & (US$ Million) Table 71. Europe Gene Therapy in CNS Disorder Revenue by Application (2027-2032) & (US$ Million) Table 72. Europe Gene Therapy in CNS Disorder Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 73. Europe Gene Therapy in CNS Disorder Revenue by Country (2021-2026) & (US$ Million) Table 74. Europe Gene Therapy in CNS Disorder Revenue by Country (US$ Million) & (2027-2032) Table 75. China Gene Therapy in CNS Disorder Revenue by Type (2021-2026) & (US$ Million) Table 76. China Gene Therapy in CNS Disorder Revenue by Type (2027-2032) & (US$ Million) Table 77. China Gene Therapy in CNS Disorder Revenue by Application (2021-2026) & (US$ Million) Table 78. China Gene Therapy in CNS Disorder Revenue by Application (2027-2032) & (US$ Million) Table 79. Asia Gene Therapy in CNS Disorder Revenue by Type (2021-2026) & (US$ Million) Table 80. Asia Gene Therapy in CNS Disorder Revenue by Type (2027-2032) & (US$ Million) Table 81. Asia Gene Therapy in CNS Disorder Revenue by Application (2021-2026) & (US$ Million) Table 82. Asia Gene Therapy in CNS Disorder Revenue by Application (2027-2032) & (US$ Million) Table 83. Asia Gene Therapy in CNS Disorder Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 84. Asia Gene Therapy in CNS Disorder Revenue by Region (US$ Million) & (2021-2026) Table 85. Asia Gene Therapy in CNS Disorder Revenue by Region (US$ Million) & (2027-2032) Table 86. SAMEA Gene Therapy in CNS Disorder Revenue by Type (2021-2026) & (US$ Million) Table 87. SAMEA Gene Therapy in CNS Disorder Revenue by Type (2027-2032) & (US$ Million) Table 88. SAMEA Gene Therapy in CNS Disorder Revenue by Application (2021-2026) & (US$ Million) Table 89. SAMEA Gene Therapy in CNS Disorder Revenue by Application (2027-2032) & (US$ Million) Table 90. SAMEA Gene Therapy in CNS Disorder Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 91. SAMEA Gene Therapy in CNS Disorder Revenue by Country (2021-2026) & (US$ Million) Table 92. SAMEA Gene Therapy in CNS Disorder Revenue by Country (US$ Million) & (2027-2032) Table 93. Research Programs/Design for This Report Table 94. Authors List of This Report Table 95. Secondary Sources Table 96. Primary Sources List of Figures Figure 1. Gene Therapy in CNS Disorder Image Figure 2. Global Gene Therapy in CNS Disorder Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gene Therapy in CNS Disorder Market Size Share 2021 VS 2025 VS 2032 Figure 4. Viral Gene Therapy Image Figure 5. Non-viral Gene Therapy Image Figure 6. Global Gene Therapy in CNS Disorder Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Gene Therapy in CNS Disorder Market Size Share 2021 VS 2025 VS 2032 Figure 8. Parkinson's Disease Image Figure 9. Huntington's Disease Image Figure 10. Batten Disease Image Figure 11. Alzheimer's Disease Image Figure 12. Global Gene Therapy in CNS Disorder Market Size (US$ Million) & (2021-2032) Figure 13. Global Gene Therapy in CNS Disorder Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Gene Therapy in CNS Disorder Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Gene Therapy in CNS Disorder Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Gene Therapy in CNS Disorder Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Gene Therapy in CNS Disorder Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Gene Therapy in CNS Disorder Revenue Market Share by Type (2021-2032) Figure 20. Global Gene Therapy in CNS Disorder Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Gene Therapy in CNS Disorder Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Gene Therapy in CNS Disorder Revenue Market Share by Application (2021-2032) Figure 23. North America Gene Therapy in CNS Disorder Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Gene Therapy in CNS Disorder Revenue Share by Type (2021-2032) Figure 25. North America Gene Therapy in CNS Disorder Revenue Share by Application (2021-2032) Figure 26. North America Gene Therapy in CNS Disorder Revenue Share by Country (2021-2032) Figure 27. United States Gene Therapy in CNS Disorder Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Gene Therapy in CNS Disorder Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Gene Therapy in CNS Disorder Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Gene Therapy in CNS Disorder Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Gene Therapy in CNS Disorder Revenue Share by Type (2021-2032) Figure 32. Europe Gene Therapy in CNS Disorder Revenue Share by Application (2021-2032) Figure 33. Europe Gene Therapy in CNS Disorder Revenue Share by Country (2021-2032) Figure 34. Germany Gene Therapy in CNS Disorder Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Gene Therapy in CNS Disorder Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Gene Therapy in CNS Disorder Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Gene Therapy in CNS Disorder Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Gene Therapy in CNS Disorder Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Gene Therapy in CNS Disorder Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Gene Therapy in CNS Disorder Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Gene Therapy in CNS Disorder Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Gene Therapy in CNS Disorder Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Gene Therapy in CNS Disorder Revenue Share by Type (2021-2032) Figure 44. China Gene Therapy in CNS Disorder Revenue Share by Application (2021-2032) Figure 45. Asia Gene Therapy in CNS Disorder Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Gene Therapy in CNS Disorder Revenue Share by Type (2021-2032) Figure 47. Asia Gene Therapy in CNS Disorder Revenue Share by Application (2021-2032) Figure 48. Asia Gene Therapy in CNS Disorder Revenue Share by Region (2021-2032) Figure 49. Japan Gene Therapy in CNS Disorder Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Gene Therapy in CNS Disorder Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Gene Therapy in CNS Disorder Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Gene Therapy in CNS Disorder Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Gene Therapy in CNS Disorder Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Gene Therapy in CNS Disorder Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Gene Therapy in CNS Disorder Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Gene Therapy in CNS Disorder Revenue Share by Type (2021-2032) Figure 57. SAMEA Gene Therapy in CNS Disorder Revenue Share by Application (2021-2032) Figure 58. SAMEA Gene Therapy in CNS Disorder Revenue Share by Country (2021-2032) Figure 59. Brazil Gene Therapy in CNS Disorder Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Gene Therapy in CNS Disorder Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Gene Therapy in CNS Disorder Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Gene Therapy in CNS Disorder Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Gene Therapy in CNS Disorder Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Gene Therapy in CNS Disorder Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Gene Therapy in CNS Disorder Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Gene Therapy in CNS Disorder Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Gene Therapy in CNS Disorder Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Gene Therapy in CNS Disorder Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Gene Therapy in CNS Disorder Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Viral Gene Therapy
  • Non-viral Gene Therapy
Applications
  • Parkinson's Disease
  • Huntington's Disease
  • Batten Disease
  • Alzheimer's Disease
Companies covered
  • Novartis AG
  • Biogen
  • Voyager Therapeutics
  • Spark Therapeutics
  • Bluebird Bio Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Gene Therapy in CNS Disorder Market by Type
  3. 1.2.1 Global Gene Therapy in CNS Disorder Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Viral Gene Therapy
  5. 1.2.3 Non-viral Gene Therapy
  6. 1.3 Gene Therapy in CNS Disorder Market by Application
  7. 1.3.1 Global Gene Therapy in CNS Disorder Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Parkinson's Disease
  9. 1.3.3 Huntington's Disease
  10. 1.3.4 Batten Disease
  11. 1.3.5 Alzheimer's Disease
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Gene Therapy in CNS Disorder Market Dynamics
  1. 2.1 Gene Therapy in CNS Disorder Industry Trends
  2. 2.2 Gene Therapy in CNS Disorder Industry Drivers
  3. 2.3 Gene Therapy in CNS Disorder Industry Opportunities and Challenges
  4. 2.4 Gene Therapy in CNS Disorder Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Gene Therapy in CNS Disorder Market Perspective (2021-2032)
  2. 3.2 Global Gene Therapy in CNS Disorder Growth Trends by Region
  3. 3.2.1 Global Gene Therapy in CNS Disorder Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Gene Therapy in CNS Disorder Market Size by Region (2021-2026)
  5. 3.2.3 Global Gene Therapy in CNS Disorder Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Gene Therapy in CNS Disorder Revenue by Players
  2. 4.1.1 Global Gene Therapy in CNS Disorder Revenue by Players (2021-2026)
  3. 4.1.2 Global Gene Therapy in CNS Disorder Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Gene Therapy in CNS Disorder Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Gene Therapy in CNS Disorder Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Gene Therapy in CNS Disorder Key Players Headquarters & Area Served
  7. 4.4 Global Gene Therapy in CNS Disorder Players, Product Type & Application
  8. 4.5 Global Gene Therapy in CNS Disorder Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Gene Therapy in CNS Disorder Market CR5 and HHI
  11. 4.6.3 2025 Gene Therapy in CNS Disorder Tier 1, Tier 2, and Tier 3
5 Gene Therapy in CNS Disorder Market Size by Type
  1. 5.1 Global Gene Therapy in CNS Disorder Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Gene Therapy in CNS Disorder Revenue by Type (2021-2032)
  3. 5.3 Global Gene Therapy in CNS Disorder Revenue Market Share by Type (2021-2032)
6 Gene Therapy in CNS Disorder Market Size by Application
  1. 6.1 Global Gene Therapy in CNS Disorder Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Gene Therapy in CNS Disorder Revenue by Application (2021-2032)
  3. 6.3 Global Gene Therapy in CNS Disorder Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Novartis AG
  2. 7.1.1 Novartis AG Company Information
  3. 7.1.2 Novartis AG Business Overview
  4. 7.1.3 Novartis AG Gene Therapy in CNS Disorder Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Novartis AG Gene Therapy in CNS Disorder Product Portfolio
  6. 7.1.5 Novartis AG Recent Developments
  7. 7.2 Biogen
  8. 7.2.1 Biogen Company Information
  9. 7.2.2 Biogen Business Overview
  10. 7.2.3 Biogen Gene Therapy in CNS Disorder Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Biogen Gene Therapy in CNS Disorder Product Portfolio
  12. 7.2.5 Biogen Recent Developments
  13. 7.3 Voyager Therapeutics
  14. 7.3.1 Voyager Therapeutics Company Information
  15. 7.3.2 Voyager Therapeutics Business Overview
  16. 7.3.3 Voyager Therapeutics Gene Therapy in CNS Disorder Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Voyager Therapeutics Gene Therapy in CNS Disorder Product Portfolio
  18. 7.3.5 Voyager Therapeutics Recent Developments
  19. 7.4 Spark Therapeutics
  20. 7.4.1 Spark Therapeutics Company Information
  21. 7.4.2 Spark Therapeutics Business Overview
  22. 7.4.3 Spark Therapeutics Gene Therapy in CNS Disorder Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Spark Therapeutics Gene Therapy in CNS Disorder Product Portfolio
  24. 7.4.5 Spark Therapeutics Recent Developments
  25. 7.5 Bluebird Bio Inc.
  26. 7.5.1 Bluebird Bio Inc. Company Information
  27. 7.5.2 Bluebird Bio Inc. Business Overview
  28. 7.5.3 Bluebird Bio Inc. Gene Therapy in CNS Disorder Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Bluebird Bio Inc. Gene Therapy in CNS Disorder Product Portfolio
  30. 7.5.5 Bluebird Bio Inc. Recent Developments
8 North America
  1. 8.1 North America Gene Therapy in CNS Disorder Revenue (2021-2032)
  2. 8.2 North America Gene Therapy in CNS Disorder Revenue by Type (2021-2032)
  3. 8.2.1 North America Gene Therapy in CNS Disorder Revenue by Type (2021-2026)
  4. 8.2.2 North America Gene Therapy in CNS Disorder Revenue by Type (2027-2032)
  5. 8.3 North America Gene Therapy in CNS Disorder Revenue Share by Type (2021-2032)
  6. 8.4 North America Gene Therapy in CNS Disorder Revenue by Application (2021-2032)
  7. 8.4.1 North America Gene Therapy in CNS Disorder Revenue by Application (2021-2026)
  8. 8.4.2 North America Gene Therapy in CNS Disorder Revenue by Application (2027-2032)
  9. 8.5 North America Gene Therapy in CNS Disorder Revenue Share by Application (2021-2032)
  10. 8.6 North America Gene Therapy in CNS Disorder Revenue by Country
  11. 8.6.1 North America Gene Therapy in CNS Disorder Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Gene Therapy in CNS Disorder Revenue by Country (2021-2026)
  13. 8.6.3 North America Gene Therapy in CNS Disorder Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Gene Therapy in CNS Disorder Revenue (2021-2032)
  2. 9.2 Europe Gene Therapy in CNS Disorder Revenue by Type (2021-2032)
  3. 9.2.1 Europe Gene Therapy in CNS Disorder Revenue by Type (2021-2026)
  4. 9.2.2 Europe Gene Therapy in CNS Disorder Revenue by Type (2027-2032)
  5. 9.3 Europe Gene Therapy in CNS Disorder Revenue Share by Type (2021-2032)
  6. 9.4 Europe Gene Therapy in CNS Disorder Revenue by Application (2021-2032)
  7. 9.4.1 Europe Gene Therapy in CNS Disorder Revenue by Application (2021-2026)
  8. 9.4.2 Europe Gene Therapy in CNS Disorder Revenue by Application (2027-2032)
  9. 9.5 Europe Gene Therapy in CNS Disorder Revenue Share by Application (2021-2032)
  10. 9.6 Europe Gene Therapy in CNS Disorder Revenue by Country
  11. 9.6.1 Europe Gene Therapy in CNS Disorder Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Gene Therapy in CNS Disorder Revenue by Country (2021-2026)
  13. 9.6.3 Europe Gene Therapy in CNS Disorder Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Gene Therapy in CNS Disorder Revenue (2021-2032)
  2. 10.2 China Gene Therapy in CNS Disorder Revenue by Type (2021-2032)
  3. 10.2.1 China Gene Therapy in CNS Disorder Revenue by Type (2021-2026)
  4. 10.2.2 China Gene Therapy in CNS Disorder Revenue by Type (2027-2032)
  5. 10.3 China Gene Therapy in CNS Disorder Revenue Share by Type (2021-2032)
  6. 10.4 China Gene Therapy in CNS Disorder Revenue by Application (2021-2032)
  7. 10.4.1 China Gene Therapy in CNS Disorder Revenue by Application (2021-2026)
  8. 10.4.2 China Gene Therapy in CNS Disorder Revenue by Application (2027-2032)
  9. 10.5 China Gene Therapy in CNS Disorder Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Gene Therapy in CNS Disorder Revenue (2021-2032)
  2. 11.2 Asia Gene Therapy in CNS Disorder Revenue by Type (2021-2032)
  3. 11.2.1 Asia Gene Therapy in CNS Disorder Revenue by Type (2021-2026)
  4. 11.2.2 Asia Gene Therapy in CNS Disorder Revenue by Type (2027-2032)
  5. 11.3 Asia Gene Therapy in CNS Disorder Revenue Share by Type (2021-2032)
  6. 11.4 Asia Gene Therapy in CNS Disorder Revenue by Application (2021-2032)
  7. 11.4.1 Asia Gene Therapy in CNS Disorder Revenue by Application (2021-2026)
  8. 11.4.2 Asia Gene Therapy in CNS Disorder Revenue by Application (2027-2032)
  9. 11.5 Asia Gene Therapy in CNS Disorder Revenue Share by Application (2021-2032)
  10. 11.6 Asia Gene Therapy in CNS Disorder Revenue by Country
  11. 11.6.1 Asia Gene Therapy in CNS Disorder Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Gene Therapy in CNS Disorder Revenue by Country (2021-2026)
  13. 11.6.3 Asia Gene Therapy in CNS Disorder Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Gene Therapy in CNS Disorder Revenue (2021-2032)
  2. 12.2 SAMEA Gene Therapy in CNS Disorder Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Gene Therapy in CNS Disorder Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Gene Therapy in CNS Disorder Revenue by Type (2027-2032)
  5. 12.3 SAMEA Gene Therapy in CNS Disorder Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Gene Therapy in CNS Disorder Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Gene Therapy in CNS Disorder Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Gene Therapy in CNS Disorder Revenue by Application (2027-2032)
  9. 12.5 SAMEA Gene Therapy in CNS Disorder Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Gene Therapy in CNS Disorder Revenue by Country
  11. 12.6.1 SAMEA Gene Therapy in CNS Disorder Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Gene Therapy in CNS Disorder Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Gene Therapy in CNS Disorder Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst